ArticleAmerican journal of cancer research2016

Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

Nandini Dey et al.PubMed ↗Full text ↗

No numbers read from the abstract.